Akdeniz University Medical Faculty

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Amyloidosis1 trial
• Atrial fibrillation1 trial
• Haemophilia1 trial
• Hidradenitis suppurativa1 trial
• High blood pressure1 trial
• IgA nephropathy1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Multiple sclerosis1 trial
• Obesity1 trial
• Prostate cancer1 trial
• and 4 more

Phase

• Phase 310 trials
• Phase 2/32 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting7 trials
• Completed4 trials
• Recruiting3 trials

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Biogen2 trials
• Hoffmann-La Roche2 trials
• Actelion1 trial
• Boehringer Ingelheim1 trial
• and 4 more

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

  Contact: Funda Sari Bahceci (principal investigator)

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· IO Biotech· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Actelion· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

  NCT03958877· Phase 3· Biogen· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

  NCT02711553· Phase 2· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

  NCT03938792· Phase 3· Pfizer· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Janssen Research & Development, LLC· Source